DEF: Tarsus Pharmaceuticals Sets 2026 Annual Meeting Date

Tarsus Pharmaceuticals, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 25, 2026, with key proposals including director elections and executive compensation.

Summary

• Tarsus Pharmaceuticals, Inc. is holding its 2026 Annual Meeting of Stockholders on Thursday, June 25, 2026, at 9:00 a.m. Pacific Daylight Time.
• The meeting will be conducted virtually, and stockholders can attend, submit questions, and vote electronically by registering in advance.
• Key proposals for the meeting include the election of four Class III directors: Wendy Yarno, Andrew Goldberg, Scott Morrison, and David E.I. Pyott.
• Stockholders will also vote on an advisory, non-binding resolution to approve the compensation of the company's named executive officers for fiscal year 2025.
• The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, will be ratified.
• The record date for determining stockholders entitled to vote is April 27, 2026.
• Proxy materials are being furnished to stockholders primarily over the Internet, with a Notice Regarding Internet Availability of Proxy Materials expected to be mailed around April 28, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it pertains to routine corporate governance and annual meeting logistics, indicating ongoing operational stability and adherence to regulatory requirements.

Positives

• The company is holding its annual meeting to ensure continued corporate governance and stockholder engagement.
• The virtual format is intended to increase stockholder attendance and participation.
• The board has nominated experienced individuals for director positions.
• The company is seeking stockholder approval for executive compensation and auditor ratification, demonstrating transparency.
• The company has a robust board structure with independent directors and specialized committees (Audit, Compensation, Nominating and Corporate Governance, Science and Technology, Commercial).

Risks

• The filing does not contain specific financial performance data for the most recent period, as it is a proxy statement focused on governance and meeting logistics.
• The election of directors is based on a plurality vote, meaning nominees with the most 'FOR' votes are elected, and withheld votes or broker non-votes do not affect the outcome for a particular nominee.

Future Outlook

The filing does not contain specific forward-looking financial guidance. It outlines upcoming proposals for the annual meeting and provides information on director nominations and executive compensation.

Management Comments

• "It is my pleasure to invite you to attend the 2026 Annual Meeting of Stockholders (the Annual Meeting) of Tarsus Pharmaceuticals, Inc., to be held on Thursday, June 25, 2026 at 9:00 a.m. (Pacific Daylight Time)."
• "Whether or not you plan to virtually attend the meeting, your vote is very important and we encourage you to vote promptly."
• "Your Board of Directors is pleased to nominate Wendy Yarno, Andrew Goldberg, Scott Morrison, and David E.I. Pyott as Class III directors on our Board of Directors."
• "Our Board of Directors also unanimously recommends a vote FOR the approval, on a non-binding advisory basis, of the compensation of our named executive officers, and FOR the ratification of the selection of Ernst & Young LLP as our independent registered public accountants."

Industry Context

StockSavvy.ai notes that Tarsus Pharmaceuticals is holding its annual meeting, a standard corporate governance event for publicly traded companies in the biopharmaceutical sector. The proposals reflect typical agenda items, including board composition, executive pay, and auditor ratification, which are crucial for investor confidence and regulatory compliance within the industry.

Management Changes

Corporate Governance

Related Party Transactions

• David E.I. Pyott, a director, previously had a consulting agreement with the Company that terminated effective February 18, 2026.
• Dr. Bobak Azamian (CEO and Chair) and Dr. William J. Link (Director) serve on the board of a privately-held eye care company in which Tarsus Pharmaceuticals has invested $3.9 million.

Stakeholder Impact

• Shareholders: Will vote on director elections, executive compensation, and auditor ratification, influencing corporate governance and management accountability.
• Management: Executive compensation is subject to advisory stockholder approval.
• Employees: Indirectly impacted by corporate governance decisions and executive compensation structures.
• Auditors: Ernst & Young LLP's appointment for fiscal year 2026 requires stockholder ratification.

Next Steps

• Stockholders are encouraged to vote their shares by internet, telephone, or mail prior to the meeting.
• Stockholders must register in advance to attend and participate in the virtual Annual Meeting.
• The company will file a Current Report on Form 8-K with the SEC within four business days after the Annual Meeting to announce the final voting results.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new financial performance data or strategic updates that would warrant a change in investment recommendation. It focuses on governance matters and upcoming proposals for stockholder vote.

Keywords

Tarsus Pharmaceuticals, Annual Meeting, Proxy Statement, Director Election, Executive Compensation, Auditor Ratification, Virtual Meeting, Stockholder Vote, Corporate Governance